EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN)
Kies M, Ghebremichael M, Katz T, Herbst R, Youssoufian H, Burtness B. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Journal Of Clinical Oncology 2007, 25: 6024-6024. DOI: 10.1200/jco.2007.25.18_suppl.6024.Peer-Reviewed Original ResearchHigh EGFR expressionEGFR expressionRecurrent SCCHNTumor samplesCisplatin-based chemotherapySquamous cell carcinomaAssociation of responsePercentage of cellsHazard ratioProgressive diseaseCisplatin therapyPatient selectionCell carcinomaHigher eGFREGFR immunoreactivityInitial cohortCetuximabChemotherapyIndependent cohortFurther enrollmentPatientsSurvival analysisTumor resistanceDako kitSCCHN